Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.
about
Alcohol use behaviors and risk of metabolic syndrome in South Korean middle-aged men.Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity.The isoflavone-rich fraction of the crude extract of the Puerariae flower increases oxygen consumption and BAT UCP1 expression in high-fat diet-fed mice.The Mediation of Hepatic Lipogenesis Through Estrogens.Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats.Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.The potential of flavonoids in the treatment of non-alcoholic fatty liver disease.Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.Soy Improves Cardiometabolic Health and Cecal Microbiota in Female Low-Fit Rats.Non-alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids.2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice.The crude extract from puerariae flower exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice.Daidzein regulates proinflammatory adipokines thereby improving obesity-related inflammation through PPARγ.Anti-obesity molecular mechanism of soy isoflavones: weaving the way to new therapeutic routes.A diet containing a high- versus low-daidzein level does not protect against liver steatosis in the obese Zucker rat model.Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats.A diet formula of Puerariae radix, Lycium barbarum, Crataegus pinnatifida, and Polygonati rhizoma alleviates insulin resistance and hepatic steatosis in CD-1 mice and HepG2 cells.Effects of three different formulae of Gamisoyosan on lipid accumulation induced by oleic acid in HepG2 cells.
P2860
Q33938686-5711B708-9D03-4AEE-A0ED-D353DD507217Q35636132-6F993219-B938-4CE0-9050-EA1B78C253EAQ36648417-0559F607-4684-49C8-BC71-6B57DA4430D1Q37446318-31117A5B-C0C5-487A-91D3-3A1994CCB0B8Q37496673-0BA1A340-1E89-4E66-9194-E66DA43F7B00Q38168505-679618E4-5F3D-4697-AF67-59DC29BC8208Q38336275-887852BB-6C9E-4D15-80EB-C975009C3086Q38432731-D09B9ECF-9539-44DB-93B2-D0261AD17F46Q38599131-6A51951C-A4EC-4A8D-8C8B-FD5A64228B1AQ38611119-1EB60B09-FC11-462B-B34C-BC4C56E9B35CQ38866384-7DE27FB8-4827-4883-92A9-098213C1C000Q40810858-9ED0FE4A-75B4-4AE0-8EFE-BF0DA1C35023Q42175184-7059EE51-7C6C-4BAC-81CC-0A17C2B51AB7Q42809120-1735D75A-B482-481F-8E58-F53470647923Q47636158-2C93BBD3-3428-4276-98D0-B5E2109F7F3AQ47845194-EA2691C6-7ED9-4987-AE56-AA443E167517Q50948793-68FA05D1-B7B4-4F1D-A7F7-D9C812517D19Q51325717-05030831-4E26-4DD4-889B-1BA65BE01C84Q52737484-DE082FF1-E99D-426B-AADF-4BEAC7B0DAF7
P2860
Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@en
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@nl
type
label
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@en
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@nl
prefLabel
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@en
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@nl
P2093
P2860
P356
P1476
Daidzein supplementation preve ...... iles and adipocyte metabolism.
@en
P2093
P2860
P2888
P304
P356
10.1038/IJO.2010.256
P407
P577
2010-12-14T00:00:00Z